Nasus Pharma Ltd
Nasus Pharma Ltd is a clinical-stage pharmaceutical company focused on developing innovative intranasal drug products. The company is based in Tel Aviv, Israel and is organized around a proprietary intranasal technology platform and a pipeline of powder-based therapeutic candidates.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueA powder-based intranasal epinephrine product candidate being developed for allergic reaction treatment.
Additional proprietary intranasal powder-based programs targeting other therapeutic areas.
Preclinical, clinical, and regulatory work required to advance product candidates toward approval.
Customers
Nasus Pharma does not sell commercial products broadly; its direct counterparties are primarily investors, clinical research vendors, and regulatory stakeholders. The eventual customers for its products would be patients, physicians, and healthcare providers that use intranasal treatments for conditions where rapid administration is clinically valuable.
Investors and financing counterparties that fund ongoing development and platform expansion.
CROs, laboratories, and consultants that support trials, manufacturing, and regulatory work.
Agencies that review clinical data and NDA submissions for NS002 and related programs.
Patients, physicians, and healthcare systems that could use approved intranasal products.
Strategy
Nasus Pharma's strategy is to advance NS002 toward pivotal study and NDA submission while broadening its intranasal platform into additional therapeutic areas. The company is trying to build a differentiated product family around powder-based intranasal administration, where faster or more convenient delivery could create clinical value versus existing options.
Clinical proof and regulatory progress are the key value drivers for a single-asset biotech platform.
A broader pipeline can reduce dependence on one candidate and increase platform optionality.
Clinical-stage development requires sustained funding before any product revenue exists.
Geography
The company is incorporated as a foreign private issuer with principal executive offices in Tel Aviv, Israel and trades in the United States on the NYSE. Its development work is centered around its Israeli base, while its capital markets access and future commercialization pathway are tied to the U.S. pharmaceutical market.
Risks
Nasus Pharma faces the typical risks of a clinical-stage pharmaceutical company: trial failure, regulatory delay, and the possibility that the product profile does not translate into approval or adoption. As a single-platform developer, it is also exposed to financing risk, concentration in a limited number of candidates, and execution risk across manufacturing, clinical operations, and NDA preparation.
- Clinical failure of NS002Impact: CriticalLikelihood: Medium
The business case depends on positive pivotal data and eventual approval for its lead candidate.
Exposure: Lead asset
- Financing dependenceImpact: HighLikelihood: High
Clinical-stage operations require recurring capital before any meaningful product sales exist.
Exposure: Operating runway
- Pipeline concentrationImpact: HighLikelihood: High
A narrow portfolio means setbacks in one program can disproportionately affect enterprise value.
Exposure: Product pipeline
- Regulatory delay or rejectionImpact: HighLikelihood: Medium
FDA review outcomes can materially affect timing, cost, and the chance of market entry.
Exposure: NDA submission and approval
Accounting
Judgemental itemsTaffix is presented separately, which affects comparability of operating results across periods.
Impact: Changes reported loss and segment presentation
Equity awards are a meaningful expense in a development-stage company and increase non-cash costs.
Impact: Raises reported operating expenses
Private placements can create issuance costs and warrant valuation effects that influence net results.
Impact: Affects equity, expenses, and dilution
Clinical and regulatory spending is expensed as incurred, making results sensitive to trial timing.
Impact: Creates period-to-period volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
ARS Pharmaceuticals, Inc.
SPRY · Pharmaceutical Preparations
ARS Pharmaceuticals is a U.S.-based biopharmaceutical company built around neffy, a needle-free intranasal epinephrine product for the emergency treatment of…
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
NeuroSense Therapeutics Ltd.
NRSNW · Pharmaceutical Preparations
Can-Fite BioPharma Ltd.
CANF · Pharmaceutical Preparations
Semnur Pharmaceuticals, Inc.
SMNR · Pharmaceutical Preparations
Last updated: 28/09/2026